Next Generation Sequencing (NGS) is a powerful technique employed for decoding large sample sequences in parallel and in a more timely and cost-effective method compared to other methods. Unlike the conventional methods of sequencing, NGS has the capacity of sequencing millions of DNA fragments within a short span, cost-effective as well as highly accurate. It also too has so many uses for example in the genetic research, genetic medicine or even just in testing diseases. Due to NGS genomics, it is easier to understand the complexities of data, analyze mutations and even perform molecular analysis of diseases.
In European countries NGS is be used broadly in health services and in research. This is commonly employed in cancer research to identify genes, as well as mutations and to design treatment to enhance patient care. Moreover, NGS is being used for diagnosis of RDs where it helps in acquiring faster rates of diagnosis of genetic disorders. Many European health systems and research institutions interest in NGS for personalized medicine, infectious diseases monitoring, and population genomics improving the precise medicine in Europe. Currently, there is growth in the incidence of cancer across the globe, where 4.4 million new cancer cases in Europe in 2020 with this number anticipated to reach 4.9 million by 2030. The main forms of cancer are lung, breast, colon, prostate and rectum. The performance of NGS in the management of NSCLC and in cancer research as a whole has led with the enhanced elucidation of molecular basis of individual cancers.
On August 2023, Almac Diagnostic Services, a member of the Almac Group, invested in expanding its NextNext-Generation Sequencing capabilities for BioPharma partners, following the purchase and installation of the first Illumina NovaSeq™ X Plus instrument in Northern Ireland and the whole island of Ireland.
In June 2024, Illumina Inc. announced that it has completed integrating the latest chemistry, XLEAP-SBS™, into all reagents for its NextSeq™ 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments.
2. Reagents & Consumables
3. Services
2. Agriculture and Animal Research
3. Drug Discovery
4. Personalized Medicine and Genetic Screening
5. Others
2. Ion Semiconductor Sequencing
3. Single-Molecule Read Time Sequencing
4. Nanopore Sequencing
5. Others
2. Pharmaceutical and Biotechnology Companies
3. Hospitals and Clinics
4. Others
2. Germany
3. Italy
4. Spain
5. United Kingdom
6. Belgium
7. Netherlands
8. Russia
9. Poland
10. Greece
11. Norway
12. Romania
13. Portugal
14. Turkey
15. Rest of Europe
2. Key Person
3. Recent Developments & Strategies
4. Product Portfolio & Product Launch in Last 1 Year
5. Revenue
2. Thermo Fisher Scientific
3. Pacific Biosciences of California
4. QIAGEN N.V
5. Roche
6. Bio-Rad Laboratories, Inc.
7. Takara Bio Inc.
8. Hamilton Company
9. Geneious,
10. BioMérieux SA.
In European countries NGS is be used broadly in health services and in research. This is commonly employed in cancer research to identify genes, as well as mutations and to design treatment to enhance patient care. Moreover, NGS is being used for diagnosis of RDs where it helps in acquiring faster rates of diagnosis of genetic disorders. Many European health systems and research institutions interest in NGS for personalized medicine, infectious diseases monitoring, and population genomics improving the precise medicine in Europe. Currently, there is growth in the incidence of cancer across the globe, where 4.4 million new cancer cases in Europe in 2020 with this number anticipated to reach 4.9 million by 2030. The main forms of cancer are lung, breast, colon, prostate and rectum. The performance of NGS in the management of NSCLC and in cancer research as a whole has led with the enhanced elucidation of molecular basis of individual cancers.
Growth Driver of the Europe Next Generation Sequencing Market
Advancements in Genomic Research
Biological and genomic development is another reason for market growth in the European Next Generation Sequencing (NGS). Sequencing processes have also benefitted from improvements in technology since these processes are faster, more accurate and cheaper to accomplish. These are enabling the researchers to work on intricate information involving the genetics and to discover new biomarkers as well as the understanding of the causes of diseases based on genetics. Advancements in this area of the credit has enhanced discoveries in personalized medicine, cancer analysis, and clinical uncommon genetic disorders. Since Europeans research institutions and ‘biotech firm make use of these technologies, the market for NGS services and products expands thus contributing to growth in the market.Increasing Prevalence of Genetic Disorders
Currently, EC increase in frequency of various genetic disorders, which leads to the growing demand for NGS. With a growing number of patients with genetic disorders - inherited cancers, rare and congenital diseases - more sharply, differentiated diagnostics and treatment plans are required. Next-generation sequencing gives extensive and precise genetic data for the formulation of these disorders’ diagnosis and treatment. This demand for the genetic testing and moving towards personalized medicine is driving the NGS market since health care providers are in search of better diagnostic tools to serve their client better.Expanding Applications in Personalized Medicine
Expansion across applications in Personalized medicine is identified as a primary growth factor in the European NGS market. As one of the leading products offering personalized medicine where treatment depends on the genetic make-up of the patient, NGS technologies provides the necessary and adequate genetic information. Personalized medicine strategies and targeted therapy applications can be accelerated through NGS since accurate determination of associations between genetic variations and therapeutic outcomes is achievable. It has been observed that with the advent of personalized medicine in the Europe, the healthcare facilities are now investing more in NGS solutions for precision in diagnosis and treatment of the patients and this has fueled the growth of the market.Germany Next Generation Sequencing Market
Germany’s NGS demand is set to continue growing as more organizations and patients take advantage of genomics and incorporate them into their medical strategies. The improvement in research capabilities and investment on biotechnology of Germany helped in the adaptation of NGS on different study area such as cancer studies, genetic disease, and individualized medicine. Analyzing the German market, the most important advantage of NGS is its possibility of high-throughput analysis, which helps research institutions and hospitals in discovering new biomarkers. Besides, grants and subsidies provided by governments for genomic research also contributes to the growth of the market. With Germany being a key player in the global healthcare industry and with more emphasis being laid on developing innovative healthcare services in Germany and especially on individualized treatment systems, the Germany NGS market is expected to experience considerable growth in the years to come owing to continuing technological advancement as well as its increasing clinical applications. This segment in 2024 is expected to dominate the research and other applications segment in Europe NGS market. The rise in the number of laboratories that are adopting sequencing-based tests, the increasing market for personalized drugs, the use of NGS for research and the rising incidences of genetic diseases. For instance, based on the data from the German Center for Lung Research, July 2024, about 2,500 newborns were diagnosed with cystic fibrosis in 2022.Europe Next Generation Sequencing Company Analysis
The top companies in the European Next-Generation Sequencing Market are Illumina, Thermo Fisher Scientific, Pacific Biosciences of California, QIAGEN N.V, Roche, Bio-Rad Laboratories, Inc., Takara Bio Inc., Hamilton Company, Geneious, and BioMérieux SA.Europe Next Generation Sequencing Company News
Jul 2024, Permanent reimbursement for next-generation sequencing (NGS) in oncology launched in Belgium.On August 2023, Almac Diagnostic Services, a member of the Almac Group, invested in expanding its NextNext-Generation Sequencing capabilities for BioPharma partners, following the purchase and installation of the first Illumina NovaSeq™ X Plus instrument in Northern Ireland and the whole island of Ireland.
In June 2024, Illumina Inc. announced that it has completed integrating the latest chemistry, XLEAP-SBS™, into all reagents for its NextSeq™ 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments.
Product -Market breakup in 3 viewpoints:
1. Instruments2. Reagents & Consumables
3. Services
Application - Market breakup in 5 viewpoints:
1. Diagnostics2. Agriculture and Animal Research
3. Drug Discovery
4. Personalized Medicine and Genetic Screening
5. Others
Technology - Market breakup in 5 viewpoints:
1. Sequencing by Synthesis2. Ion Semiconductor Sequencing
3. Single-Molecule Read Time Sequencing
4. Nanopore Sequencing
5. Others
End-Users -Market breakup in 4 viewpoints:
1. Academic and Clinical Research Centers2. Pharmaceutical and Biotechnology Companies
3. Hospitals and Clinics
4. Others
Countries - Europe Next-Generation Sequencing (NGS) Market of 15 Countries:
1. France2. Germany
3. Italy
4. Spain
5. United Kingdom
6. Belgium
7. Netherlands
8. Russia
9. Poland
10. Greece
11. Norway
12. Romania
13. Portugal
14. Turkey
15. Rest of Europe
Key players have been covered from 5 Viewpoints:
1. Overviews2. Key Person
3. Recent Developments & Strategies
4. Product Portfolio & Product Launch in Last 1 Year
5. Revenue
Company Analysis:
1. Illumina2. Thermo Fisher Scientific
3. Pacific Biosciences of California
4. QIAGEN N.V
5. Roche
6. Bio-Rad Laboratories, Inc.
7. Takara Bio Inc.
8. Hamilton Company
9. Geneious,
10. BioMérieux SA.
Table of Contents
1. Introduction2. Research & Methodology3. Executive Summary5. Europe Next Generation Sequencing Market
4. Market Dynamics
6. Market Share
7. Products
8. Application
9. Technology
10. End User
11. Countries
12. Porter's Five Forces Analysis
13. SWOT Analysis
14. Key Players Analysis
Companies Mentioned
- Illumina
- Thermo Fisher Scientific
- Pacific Biosciences of California
- QIAGEN N.V
- Roche
- Bio-Rad Laboratories, Inc.
- Takara Bio Inc.
- Hamilton Company
- Geneious,
- BioMérieux SA.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 4.58 Billion |
| Forecasted Market Value ( USD | $ 12.95 Billion |
| Compound Annual Growth Rate | 12.2% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 10 |
